Study of Verinurad in Heart Failure With Preserved Ejection Fraction

PHASE2CompletedINTERVENTIONAL
Enrollment

159

Participants

Timeline

Start Date

May 19, 2020

Primary Completion Date

April 29, 2022

Study Completion Date

April 29, 2022

Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
DRUG

Verinurad

"The treatment will be titrated in 3 steps for target low dose (3 mg), intermediate dose (7.5 mg) and high dose (12mg) of verinurad.~Drug: Allopurinol The treatment will be titrated in 3 steps. Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol."

DRUG

Allopurinol

Study treatments will be titrated in 3 steps: Low dose (100mg), intermediate (200mg) and high dose (300mg) of allopurinol

DRUG

Placebo for verinurad

Matching Capsule

DRUG

Placebo for allopurinol

Matching tablet

Trial Locations (58)

1000

Research Site, Sofia

1090

Research Site, Vienna

1431

Research Site, Sofia

2000

Research Site, Rosario

3220

Research Site, Geelong

4004

Research Site, Plovdiv

4032

Research Site, Chermside

4064

Research Site, Milton

5042

Research Site, Bedford Park

7600

Research Site, Mar del Plata

8036

Research Site, Graz

10789

Research Site, Berlin

13353

Research Site, Berlin

23510

Research Site, Norfolk

26426

Research Site, Gangwon-do

27157

Research Site, Winston-Salem

28644

Research Site, Cheongju-si

32127

Research Site, Port Orange

32545

Research Site, Bad Oeynhausen

33024

Research Site, Pembroke Pines

33135

Research Site, Miami

37075

Research Site, Göttingen

76000

Research Site, Querétaro

90502

Research Site, Torrance

91324

Research Site, Northridge

91344

Research Site, Granada Hills

93053

Research Site, Regensburg

97078

Research Site, Würzburg

97742

Research Site, Brezno

195067

Research Site, Saint Petersburg

199226

Research Site, Saint Petersburg

624002

Research Site, Aramil

630055

Research Site, Novosibirsk

634012

Research Site, Tomsk

650002

Research Site, Kemerovo

C1006ACC

Research Site, CABA

C1119ACN

Research Site, CABA

C1425AGC

Research Site, CABA

B7600GNY

Research Site, Mar del Plata

G1G 3Y8

Research Site, Québec

G1V 4G5

Research Site, Québec

G2J 0C4

Research Site, Québec

G3K 2P8

Research Site, Québec

85-079

Research Site, Bydgoszcz

89-600

Research Site, Chojnice

32-500

Research Site, Chrzanów

20-362

Research Site, Lublin

43-100

Research Site, Tychy

02-097

Research Site, Warsaw

02-637

Research Site, Warsaw

04-628

Research Site, Warsaw

984 01

Research Site, Lučenec

080 01

Research Site, Prešov

08901

Research Site, Svidník

03080

Research Site, Seoul

03722

Research Site, Seoul

05505

Research Site, Seoul

08308

Research Site, Seoul

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY